Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab

BACKGROUND: KRAS mutations in metastatic colorectal cancer (mCRC) define a subset of tumors that have primary resistance to anti-EGFR-based therapy. Data concerning whether different KRAS mutations may also have a prognostic value are lacking. Furthermore, novel KRAS G12C inhibitors are currently in...

Descripción completa

Detalles Bibliográficos
Autores principales: Giampieri, Riccardo, Lupi, Alessio, Ziranu, Pina, Bittoni, Alessandro, Pretta, Andrea, Pecci, Federica, Persano, Mara, Giglio, Enrica, Copparoni, Cecilia, Crocetti, Sonia, Mandolesi, Alessandra, Faa, Gavino, Coni, Pierpaolo, Scartozzi, Mario, Berardi, Rossana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514824/
https://www.ncbi.nlm.nih.gov/pubmed/34660299
http://dx.doi.org/10.3389/fonc.2021.736104

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8514824/
https://www.ncbi.nlm.nih.gov/pubmed/34660299
http://dx.doi.org/10.3389/fonc.2021.736104

Ejemplares similares